We perform functional imaging examinations on patients using radioactively labeled pharmaceuticals (radiopharmaceuticals). Using scintigraphy, Single Photon Emission Tomography (SPECT) and Positron Emission Tomography (PET) we are able to visualize biochemical processes in the body. Due to the combination with anatomic cross-sectional imaging examinations like CT and MRI in the form of hybrid imaging systems we are able to localize these processes precisely. Applications of hybrid imaging with PET/CT and PET/MR were and are being co-developed by our service, and we were the first world-wide to clinically use PET/CT in tumor- and heart-imaging. In addition to diagnostic imaging examinations of all organs we are also performing therapies with radiopharmaceuticals which are similar to those use in diagnosis (so called theragnostics). Theragonstic therapies are mainly used in benign and malignant thyroid disease, but increasingly also in other tumors.
The new "Revolution CT" in use in the Department of Nuclear Medicine.